Limits...
Investments in sexually transmitted infection research, 1997-2013: a systematic analysis of funding awarded to UK institutions.

Head MG, Fitchett JR, Cassell JA, Atun R - J Glob Health (2015)

Bottom Line: Funding for non-HIV STIs has declined in the three most recent years of this data set.The investment for HIV research awarded to UK institutions correlates with the high global burden, but other STIs are relatively neglected, including gonorrhoea and syphilis.Future STI funding should be better aligned with burden while addressing the emerging risk of antimicrobial resistance in Neisseria gonorrhoeae and outbreaks of other pathogens.

View Article: PubMed Central - PubMed

Affiliation: University College London, Farr Institute for Health Informatics, London, UK.

ABSTRACT

Background: We report the first study that analyses public and philanthropic investments awarded to UK institutions for research related to sexually transmitted infections (STIs).

Methods: We systematically searched award data from the major funders for information on all infectious disease research funding awarded in 1997-2013. The STI-related projects were identified and categorised by pathogen, disease and type of science along the research pipeline from preclinical to translational research.

Findings: We identified 7393 infection-related awards with total investment of GBP 3.5 billion. Of these, 1238 awards (16.7%) covering funding of GBP 719.1 million (20.5%) were for STI research. HIV as an STI received GBP 465 million across 719 studies; non-HIV STIs received GBP 139 million across 378 studies. The Medical Research Council provided greatest investment (GBP 193 million for HIV, GBP 45 million for non-HIV STIs). Preclinical awards totalled GBP 233 million (37.1%), whilst translational research received GBP 286 million (39.7%). Substantial proportions of HIV investment addressed global health research (GBP 265 million), vaccinology (GBP 110 million) and therapeutics (GBP 202 million). For other STIs, investments focused on diagnostics (GBP 45 million) and global health (GBP 27 million). Human Papilloma Virus research received GBP 58 million and chlamydia GBP 24 million. Funding for non-HIV STIs has declined in the three most recent years of this data set.

Conclusions: The investment for HIV research awarded to UK institutions correlates with the high global burden, but other STIs are relatively neglected, including gonorrhoea and syphilis. Future STI funding should be better aligned with burden while addressing the emerging risk of antimicrobial resistance in Neisseria gonorrhoeae and outbreaks of other pathogens.

No MeSH data available.


Related in: MedlinePlus

Investments on HIV (A) and other sexually–transmitted infection (B) research awarded to the UK over time and by type of science (x1 HIV and x2 STI cross–disciplinary studies not shown here).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4544235&req=5

Figure 1: Investments on HIV (A) and other sexually–transmitted infection (B) research awarded to the UK over time and by type of science (x1 HIV and x2 STI cross–disciplinary studies not shown here).

Mentions: Of this, GBP 596.8 million (83.0%) was related to HIV across 873 studies (70.5%), and GBP 155.6 million (21.6%) was invested in other STIs over 378 studies (32.5%). Median study funding for HIV research was GBP 173 109 (IQR GBP 39 374–454 801); median study funding for other STIs was GBP 105 115 (IQR GBP 17 827–251 356). A wide variety of funders contributed greatly to the sum funding, but the Medical Research Council invested the greatest amount for both HIV (GBP 192.8 million, 32.0%) and for other STIs (GBP 45.2 million, 29.0%). Annual funding is volatile with no consistent temporal trend in funding awards for either HIV or other STI research, and it appears as though funding for non–HIV STIs is declining in the most recent years of this data set (Figure 1).


Investments in sexually transmitted infection research, 1997-2013: a systematic analysis of funding awarded to UK institutions.

Head MG, Fitchett JR, Cassell JA, Atun R - J Glob Health (2015)

Investments on HIV (A) and other sexually–transmitted infection (B) research awarded to the UK over time and by type of science (x1 HIV and x2 STI cross–disciplinary studies not shown here).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4544235&req=5

Figure 1: Investments on HIV (A) and other sexually–transmitted infection (B) research awarded to the UK over time and by type of science (x1 HIV and x2 STI cross–disciplinary studies not shown here).
Mentions: Of this, GBP 596.8 million (83.0%) was related to HIV across 873 studies (70.5%), and GBP 155.6 million (21.6%) was invested in other STIs over 378 studies (32.5%). Median study funding for HIV research was GBP 173 109 (IQR GBP 39 374–454 801); median study funding for other STIs was GBP 105 115 (IQR GBP 17 827–251 356). A wide variety of funders contributed greatly to the sum funding, but the Medical Research Council invested the greatest amount for both HIV (GBP 192.8 million, 32.0%) and for other STIs (GBP 45.2 million, 29.0%). Annual funding is volatile with no consistent temporal trend in funding awards for either HIV or other STI research, and it appears as though funding for non–HIV STIs is declining in the most recent years of this data set (Figure 1).

Bottom Line: Funding for non-HIV STIs has declined in the three most recent years of this data set.The investment for HIV research awarded to UK institutions correlates with the high global burden, but other STIs are relatively neglected, including gonorrhoea and syphilis.Future STI funding should be better aligned with burden while addressing the emerging risk of antimicrobial resistance in Neisseria gonorrhoeae and outbreaks of other pathogens.

View Article: PubMed Central - PubMed

Affiliation: University College London, Farr Institute for Health Informatics, London, UK.

ABSTRACT

Background: We report the first study that analyses public and philanthropic investments awarded to UK institutions for research related to sexually transmitted infections (STIs).

Methods: We systematically searched award data from the major funders for information on all infectious disease research funding awarded in 1997-2013. The STI-related projects were identified and categorised by pathogen, disease and type of science along the research pipeline from preclinical to translational research.

Findings: We identified 7393 infection-related awards with total investment of GBP 3.5 billion. Of these, 1238 awards (16.7%) covering funding of GBP 719.1 million (20.5%) were for STI research. HIV as an STI received GBP 465 million across 719 studies; non-HIV STIs received GBP 139 million across 378 studies. The Medical Research Council provided greatest investment (GBP 193 million for HIV, GBP 45 million for non-HIV STIs). Preclinical awards totalled GBP 233 million (37.1%), whilst translational research received GBP 286 million (39.7%). Substantial proportions of HIV investment addressed global health research (GBP 265 million), vaccinology (GBP 110 million) and therapeutics (GBP 202 million). For other STIs, investments focused on diagnostics (GBP 45 million) and global health (GBP 27 million). Human Papilloma Virus research received GBP 58 million and chlamydia GBP 24 million. Funding for non-HIV STIs has declined in the three most recent years of this data set.

Conclusions: The investment for HIV research awarded to UK institutions correlates with the high global burden, but other STIs are relatively neglected, including gonorrhoea and syphilis. Future STI funding should be better aligned with burden while addressing the emerging risk of antimicrobial resistance in Neisseria gonorrhoeae and outbreaks of other pathogens.

No MeSH data available.


Related in: MedlinePlus